Improving the production of gene therapy vectors using synthetic peptides
Official title: Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes
Funded at Synvivia, INC. · NIH-11067394 · Data updated 2026-11-12
This study is working on improving how we make special viruses used in gene therapy, so that patients can get better and more affordable treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Synvivia, INC. NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project start | December 15, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,640,169 |
| NIH project number | 1R44GM158472-01 |
| Project ID | NIH-11067394 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with inherited disorders or chronic illnesses that could potentially be treated with AAV-based gene therapies.
✕Less likely to help
Patients who do not have conditions treatable by gene therapy or those not eligible for AAV-based treatments may not benefit from this research.
What this research studies
This research focuses on enhancing the manufacturing process of adeno-associated virus (AAV) vectors, which are crucial for gene therapy. By utilizing a novel platform that identifies cyclic peptides, the project aims to increase both the yield and quality of these vectors. The approach involves optimizing the conditions under which these vectors are produced, addressing common challenges such as low yield and high costs. Patients may benefit from more accessible and effective gene therapies as a result of improved manufacturing techniques.
Why it matters
Potential benefit: If successful, this research could lead to more efficient and cost-effective gene therapies for a variety of inherited disorders and chronic illnesses.
How similar studies have gone: Previous research has shown promise in optimizing vector production methods, but this specific approach using synthetic peptides is relatively novel.
Where this research is happening
-
Synvivia, INC.
Berkeley, United States Active
Researchers
- Principal investigator: Huang, Charlie — Synvivia, INC.
- Study coordinator: Huang, Charlie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.